menu
    • menu

    Company profile for Immune-Onc Therapeutics

    Pfanstiehl, a global leader in the manufacture of cGMP high purity, low endotoxin, low metals (HPLE-LM)TM injectable grade excipients.

    Virtual Booth

    Contact Supplier

    Global Pharma Healthcare: Setting the global benchmark in quality, innovation, and care

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Virtual Booth

    Contact Supplier

    Farmak works in the development, production and marketing of APIs, Intermediates & Specialties// FDA inspected.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Equipped with a unique understanding of the immune suppressive dynamics that allow cancer cells to grow and spread in the body, we are moving beyond T-cell targeted therapies to develop novel biotherapeutics that navigate and disarm immune suppression and tumor infiltration. Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute ...
    Equipped with a unique understanding of the immune suppressive dynamics that allow cancer cells to grow and spread in the body, we are moving beyond T-cell targeted therapies to develop novel biotherapeutics that navigate and disarm immune suppression and tumor infiltration. Immune-Onc’s lead program, an antibody targeting an immune inhibitory receptor, is being explored as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Immune-Onc TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    795 San Antonio Road, Palo Alto, CA 94303
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.immune-onc.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immune-Onc Doses 1st Patient In IO-108 Ph 1b/2 Liver Study With Roche
    Immune-Onc Doses 1st Patient In IO-108 Ph 1b/2 Liver Study With Roche

    27 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250227540556/en

    BUSINESSWIRE
    27 Feb 2025
    Share Share
    Immune-Onc Presents Promising IO-202 Data in CMML Patients at ASH
    Immune-Onc Presents Promising IO-202 Data in CMML Patients at ASH

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241209116440/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Immune-Onc Presents Positive IO-202 Data In CMML At EHA 2024
    Immune-Onc Presents Positive IO-202 Data In CMML At EHA 2024

    14 Jun 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240614920813/en

    BUSINESSWIRE
    14 Jun 2024
    Share Share
    Immune-Onc Presents IO-202 CMML Data At EHA 2024 Congress
    Immune-Onc Presents IO-202 CMML Data At EHA 2024 Congress

    14 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240514327862/en

    BUSINESSWIRE
    14 May 2024
    Share Share
    Immune-Onc Announces Orphan Drug Designation Granted by US FDA for IO-202
    Immune-Onc Announces Orphan Drug Designation Granted by US FDA for IO-202

    21 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240221174545/en

    BUSINESSWIRE
    21 Feb 2024
    Share Share
    Immune-Onc Therapeutics Announces Trial Collaboration to Evaluate IO-108
    Immune-Onc Therapeutics Announces Trial Collaboration to Evaluate IO-108

    20 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240214042519/en

    BUSINESSWIRE
    20 Feb 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search